Sorrento Therapeutics, Inc.
ANTI-OX40 BINDING PROTEINS
Last updated:
Abstract:
The present disclosure provides anti-OX40 antibodies, and antigen-binding portions thereof. In certain embodiments, the antibodies or fragments thereof, are used for the treatment of cancer.
Status:
Application
Type:
Utility
Filling date:
17 Aug 2020
Issue date:
10 Dec 2020